Seeking Alpha

wild4ctix

wild4ctix
Send Message
View as an RSS Feed
View wild4ctix's Comments BY TICKER:
Latest  |  Highest rated
  • Cellceutix's Fundamental Strength Outweighs Market Cap [View article]
    Well researched and well stated. Thanks for presenting the facts. Quite refreshing. I am LONG CTIX.
    Jun 19, 2015. 11:45 AM | 9 Likes Like |Link to Comment
  • Kevetrin Will Be A Major Part Of The Answer To Trillions Of Prayers! [View instapost]
    Thanks ellaruth...always appreciate your insight and agree that " our time is coming " !
    Apr 21, 2015. 02:37 PM | Likes Like |Link to Comment
  • Cellceutix: Comparing Brilacidin With SoC Daptomycin [View article]
    WOW...the resume BS again. SO predictable.

    DISCLAIMER : I'm REEEEEAAAAAAAAAAAALLLL... LONG CTIX !
    Apr 21, 2015. 02:13 PM | 9 Likes Like |Link to Comment
  • Wonderful Copenhagen Beckons Cellceutix To Sing It's Story [View instapost]
    Of course it is " UNE " , that's why Harvard's Dana Farber & Beth Israel & MD Anderson are all working with Cellceutix. I think everyone would agree that those prestigious Medical organizations ALWAYS choose SCAM companies to partner with and commit their $$$ and resources. Seriously, surely you can come up with something more compelling than " IT'S A SCAM, RUN, PANIC, DANGER " ha-ha. How about the office furniture ? Any depreciation issues ? Better develop something BETTER as your time is diminishing quickly. Ella Ruth, I always appreciate your Knowledge of the company and it's potential. And I love your writing style. Thank you. BTW, " UNE " IMO, this is the most DE-risked DEVELOPING Biotech I've ever seen and I'm OLD ! disclaimer : I am LONG CTIX !
    Mar 30, 2015. 08:11 AM | 2 Likes Like |Link to Comment
  • An Interview With Cellceutix CEO Leo Ehrlich [View article]
    Thanks Karin. Always refreshing to read an interview that reflects both intelligent and compelling questions that shareholders want responses to......and read the candid and factual responses from IMO the BEST developing BIOTECH CEO & leadership ever. I've never seen a company accomplish so much with so little. WOW ! And with the imminent up listing and the addition of new Board members, I cannot express my excitement re: the future of Cellceutix. Shareholders will see significant investment returns and more importantly, countless lives will be saved. It is just the BEGINNING ! Thanks again Karin.
    Feb 9, 2015. 11:44 AM | 5 Likes Like |Link to Comment
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon [View article]
    Thanks for conveying Events and Results that HAVE occurred and not using comparisons that have ZERO impact on the PROVEN success to date. The potential of Cellceutix and its lineup of drug compounds is off the chart ? Even with some chairs, desks and tables that have depreciated, Hahahaha. This ain't BLEAK Street......This is OPPORTUNITY Street. And the upcoming Nasdaq uplisting and Institutional buying we may just see some " gold paving " on our street.
    Jan 30, 2015. 07:31 AM | 3 Likes Like |Link to Comment
  • Cellceutix: A December To Remember May Turn Into A 2015 To Forget For CTIX [View article]
    Question for the author :

    If Johnny had 3 tables and 4 desks and one Beaker and he loaned two tables to Mary and one desk to Butch, how much vodka would he have to pour into the beaker and chug it in order for your article to make sense ?
    Jan 23, 2015. 04:35 PM | 11 Likes Like |Link to Comment
  • Cellceutix: A December To Remember May Turn Into A 2015 To Forget For CTIX [View article]
    Here are some other comments from a knowledgeable and successful investor that has been following it since 2011....

    Cellceutix just reported that in its 9th cohort a spleen lesion metastasis has been stabilized in a stage 4 Ovarian cancer patient. Ovarian cancer is the deadliest of gynecological cancers and is one of the leading causes of cancer-related death in women. This is a big breakthrough in cancer research as Kevetrin is only in a Phase 1 safety study and researchers are not looking for tumor shrinkage. Kevetrin is unlike any other chemotherapy or immunotherapy compounds, it is non genotoxic with no hematological, hepatic, or renal toxicity in patients. As a completely new class of chemistry in medicine, Kevetrin has significant potential to be a major breakthrough in the treatment of solid tumors. Mechanism of action studies showed Kevetrin's unique ability to affect both wild and mutant types of p53 (often referred to as the "Guardian Angel Gene" or the "Guardian Angel of the Human Genome") and that Kevetrin strongly induced apoptosis (cell death). p53 is an important tumor suppressor that acts to restrict proliferation by inducing cell cycle checkpoints, apoptosis, or cellular senescence. Dana Farber has just approved dosing to 450mg/m2 as well as asked the company to prepare a publication.

    Cellceutix is not a one trick pony like 99.9% of the biotech company's out there. They also have a drug called Brilacidin. Brilacidin is a revolutionary drug in that it is a platform for many indications. It is a first-in-class small molecule in a completely novel class of drug called defensin-mimetic. The drug has a unique mechanism of action to imitate the body's front-line immunological defense, meaning that it selectively targets and destroys bacteria and not mammalian cells. Brilacidin is rapidly bactericidal which means it decreases the chance of the bacteria becoming resistant. Clinical trials and laboratory research showed Brilacidin as a disruptive technology that demonstrated potent, broad-spectrum activity against multiple Gram-positive pathogens as well as Gram-negative pathogens. Brilacidin has just successfully completed a Phase 2B clinical trial for ABSSSI showing a one-time dose of Brilacidin achieving statistically comparable results to the seven-day dosing regimen for the current gold standard treatment for ABSSSI, which sells about $1 billion a year of their drug, branded as Cubicin. In early December, Brilacidin received the coveted FDA QIDP designation. Also, Brilacidin is set to begin a Phase 2 clinical trial for Brilacidin-OM, an oral rinse for the prevention of Oral Mucositis (OM). This is very significant as there currently are no prophylaxes for OM, positioning Cellceutix as having a potential monopoly for the millions of sufferers of OM each year.

    Let us also not forget about Prurisol, Cellceutix anti-Psoriasis drug that just successfully completed a Phase 1 crossover trial and is set to begin a Phase 2/3 clinical trial as treatment for moderate to severe psoriasis.

    Cellceutix now has been aggressively moving forward with Kevetrin, Brilacidin, and Prurisol. Putting conservative values on Cellceutix's drugs at their current stages of development. I would place a $500 million conservative valuation on Kevetrin considering both the positive news being released from its clinical trial as well as the multi-billion dollar valuations of early stage immunotherapy cancer therapies, an additional $500 million for Brilacidin (just for the ABSSSI indication) as Brilacidin is potentially the best gram positive antibiotic out there and also considering Merck's $9.5 Billion dollar acquisition of Cubist as well as Durata Therapeutics being acquired for over $600 million dollars. I would place an additional $200 million dollar valuation on its other compounds as they are set to begin Phase 2 clinical trials for Oral Mucisitis, Proctitis, and Psoriasis. However this valuation can soon rise dramatically as clinical trials begin.

    Hope that helps Chris. BTW, now that its' down...jump in...the water is fine. I'm LONG CTIX !
    Jan 23, 2015. 02:41 PM | 6 Likes Like |Link to Comment
  • Cellceutix: A December To Remember May Turn Into A 2015 To Forget For CTIX [View article]
    Bring on all the hit pieces that conveniently leave out compelling events and outcomes that Cellceutix has accomplished to date. It provides opportunities for the knowledgeable investors ( that ARE cognizant of Cellceutix, its' Leadership and Pipeline ) to buy MORE at lower prices. I will admit that I now feel very different ( negatively different ) about the objectivity of Seeking Alpha. You would not allow Alan Harris to publish his article ( you indicated too positive ) however you publish this article. All I can say is WOW....I guess what people have been telling me for months is right on. Hate it ! Disclosure : I'm LONG CTIX but SO SHOCKED that YOU ARE SHORT CTIX ! HAHAHAHAHAHAHAHAHAHAHA... NOT !
    Jan 23, 2015. 11:16 AM | 9 Likes Like |Link to Comment
  • Cellceutix Overvalued By 90-99% [View article]
    Hahahahaha.....please SHORT it more ....and get all your Pals to short it as well ! The shareholders that actually understand the compelling VALUE of Cellceutix and its pipeline will so appreciate it and forever THANK YOU ! BTW....Worst SA article ( as it relates to leaving out facts ) I have ever read. Good Luck ! You are going to need it in about 2 weeks, Hahahahahaha.
    Jan 2, 2015. 06:21 PM | 18 Likes Like |Link to Comment
  • Reason's AbbVie Could Be Staring At Cellceutix [View instapost]
    Excellent Observation ellaruth. Thanks for sharing Smart and Considerate Young Lady !
    Dec 4, 2014. 10:21 AM | Likes Like |Link to Comment
  • Why Analysts & Financial Journalists Are Chicken Of Brilacidin? [View instapost]
    Thanks for another well researched and well written article. I enjoy both your knowledge and willingness to share your opinions and insight in a way that is fun to read while provoking thoughts and excitement ( for the reader ) about the potential of Cellceutix. Looking forward to the published final results of the B trial and especially looking forward to 2015 that has so many positive events forthcoming. Some that are potentially BLAST OFF type, ha-ha.

    Thanks again ....david
    Nov 30, 2014. 02:32 PM | Likes Like |Link to Comment
  • Kevetrin :The LeBron James Of Oncology [View instapost]
    ellaruth,
    Thanks for another compelling article about Kevetrin's potential. Why do I not get alerts from Seeking Alpha when you have new "stocktalks"? I have signed up and I get alerts from SA when other Cellceutix articles are published. Thanks in advance for your response.....david
    Jul 26, 2014. 07:10 AM | Likes Like |Link to Comment
  • Convenient Kevetrin Amnesia: Gina Kolata, Andrew Baum And Ben Hirschler  [View instapost]
    Greetings Ellaruth and thanks for another very well written article. You have once again articulated in a straightforward manner why Cellceutix and Kevetrin should be in the ring with the other contenders. Special " K " unquestionably has KO power .....well at least in ALL the trials that it has been in previously. I know I know.... " Rats lie and Monkeys exaggerate " but given the fact that Kevetrin was effective on MULTIPLE types of cancers in those trials and that it is NOW finishing the 8th Cohort in human trials at Dana Farber....with all stage 4 HUMAN patients......and at dosage levels that are NOW equivalent in Humans to the levels that saw efficacy and tumor shrinkage in the animals, well I say, " we deserve more recognition than what we have " ! Thanks so much for you helping to do JUST THAT ! Love your writing style. You're BRIGHT and FUNNY ! Skull & Bones...HAHAHAHAHAHAHA... I'm laughing to keep from crying.......GULP........ did you see my alias...so you can only imagine my.... GULP.....investment...... TGIF Ellaruth and have a great week-end too ! GOD BLESS YOU ELLARUTH...... YOU ROCK YOUNG LADY !
    Jul 25, 2014. 08:42 AM | Likes Like |Link to Comment
  • DSMB gives thumbs up for continuation of brilacidin trial [View news story]
    ONE WORD :

    " GAIN " ! Not just FDA relevance but GAIN in every imaginable sense of the word !

    Cellceutix is preparing to ROCK this space and a couple of very key others sooner than most may think. ALL in my opinion and as always " Buyer Beware " but I have been tuned to this company and its' COMPELLING Leadership and Pipeline for many years. My money is aligned with my tag name. GET IT ?

    "GAIN "....in EVERY WAY !
    Jul 7, 2014. 08:25 AM | 1 Like Like |Link to Comment
COMMENTS STATS
37 Comments
121 Likes